Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Chari Highlights Emerging Options in Heavily Pretreated Myeloma

January 26th 2019

Ajai Chari, MD, discusses novel treatment approaches for patients with heavily pretreated multiple myeloma.

Selinexor/Daratumumab Combo Shows Promise in Relapsed/Refractory Myeloma

January 22nd 2019

Cristina Gasparetto, MD, discusses the combination of daratumumab, selinexor, and dexamethasone in patients with multiple myeloma who have previously received ≥3 lines of therapy, which include an immunomodulatory agent and a proteasome inhibitor.

FDA Approval Sought for Daratumumab/Rd for Frontline Transplant-Ineligible Myeloma

January 22nd 2019

A supplemental Biologics License Application (sBLA) has been initiated with the FDA for daratumumab (Darzalex) for use in combination with lenalidomide (Revlimid) and dexamethasone (DRd) for the treatment of certain patients with multiple myeloma.

Dr. Jagannath on Treatment Advances in Transplant-Ineligible Patients With Myeloma

January 22nd 2019

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the progress that has been made in transplant-ineligible patients with multiple myeloma.

PFS Benefit Confirmed With Daratumumab Plus VMP in Newly Diagnosed Myeloma

January 22nd 2019

Maria-Victoria Mateos, MD, PhD, discusses the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.

Real-World Evidence Supports Split Daratumumab Dosing in Myeloma

January 21st 2019

Robert M. Rifkin, MD, highlights the results of a trial evaluating the safety of split-dosing administration of daratumumab in patients with multiple myeloma.

Dr. Chari on Treatment of Penta-Refractory Patients With Myeloma

January 19th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Hospital, discusses the treatment of patients with penta-refractory multiple myeloma.

Dr. Wong on an Investigational Antibody-Drug Conjugate in Multiple Myeloma

January 18th 2019

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

Controversy Adds Caution to CRISPR Editing in United States

January 17th 2019

The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.

Novel Therapies Under Investigation in Multiple Myeloma

January 17th 2019

The ELOQUENT-3 Trial in R/R Multiple Myeloma

January 17th 2019

Improving Rates of Relapse in Multiple Myeloma

January 17th 2019

Managing Heavily Pretreated R/R Multiple Myeloma

January 17th 2019

Relapsed/Refractory Multiple Myeloma: Switching Therapy

January 17th 2019

Relapsed/Refractory Multiple Myeloma: Optimal Therapy

January 17th 2019

Options for Maintenance Therapy in Multiple Myeloma

January 17th 2019

Induction Therapy Considerations in Multiple Myeloma

January 17th 2019

Treating Transplant-Ineligible Multiple Myeloma

January 17th 2019

Novel Therapies & Transplants in Multiple Myeloma

January 17th 2019

Role of MRD Assessment in Multiple Myeloma

January 17th 2019